OVERVIEW

Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes Mellitus: A Comprehensive Review of How to Weigh the Options, Select the Right Patients, and Maximize Benefits is organized by Paradigm Medical Communications, LLC and will be held from Nov 05, 2018 - Nov 05, 2019.

Target Audience
This activity has been designed to address the educational needs of endocrinologists and other specialists who manage patients with type 2 diabetes. It will also benefit other healthcare professionals, such as primary care physicians, certified diabetes educators, nurse practitioners, and PAs, who are interested in the management of patients with type 2 diabetes.

Physician Credit Designation Statement:
The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit.

PA Continuing Education:
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society

Statement of Need:
Despite demonstration of robust glycemic and extraglycemic benefits, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remain underutilized in type 2 diabetes mellitus (T2DM). A confluence of data and expert opinion strongly point to both the desire and need for specialist education on the intensification of T2DM treatment plans that include GLP-1 RAs, when appropriate, to enhance patient outcomes. This educational activity will address the nuances of GLP-1 RA therapy, providing a scientific, guideline-based, and expert-endorsed foundation for differentiating and selecting among current and emerging options, including newly available fixed-ratio insulin/GLP-1 RA injection combinations, with an emphasis on the most recent data. It will also provide strategies for overcoming barriers to injectable therapy.

Learning Objectives:
Upon proper completion of this activity, participants should be better able to:
• Describe the mechanisms by which current and emerging glucagon-like peptide-1 receptor agonists exert beneficial effects on patients with type 2 diabetes.
• Differentiate among the current and emerging glucagon-like peptide-1 receptor agonists based on pharmacology, dosing, efficacy, safety, and extraglycemic effects.
• Select appropriate candidates for glucagon-like peptide-1 receptor agonist therapy based on: current recommendations derived from guidelines, algorithms, and position statements; agent properties; and patient characteristics and preferences.
• Outline clinician-patient communication strategies to initiate and foster patient adoption of, and adherence to, appropriate, individualized antihyperglycemic treatment.